MTOR and nonpapillary renal cell carcinoma: A 2016 study of 31 patients with metastatic ccRCC treated with a VEGFR-targeting agent found that patients that experienced a duration of response longer than 21 months had a significantly higher frequency of PBRM1 mutations, while this effect was not observed with mTOR inhibitors [34].